The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024: Rahway, New Jersey Saturday, October ...

DefenAge Skincare is excited to announce the launch of its newest innovation, the 12-Factor Revitalizing Lip Enhancer. Powered by DefenAge's patented Age-Repair Defensins®, this groundbreaking lip ...

We recently published a list of 7 Best Nano Cap Stocks To Invest In. In this article, we are going to take a look at where ...

Activist hedge fund Starboard Value's chief investment officer Jeffrey Smith said on Tuesday that drugmaker Pfizer Inc ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...